Advertisement

Clinical Drug Investigation

, Volume 36, Issue 2, pp 97–107 | Cite as

Domperidone and Risk of Ventricular Arrhythmia and Cardiac Death: A Systematic Review and Meta-analysis

  • Nattawut LeelakanokEmail author
  • Andrea Holcombe
  • Marin L. Schweizer
Systematic Review

Abstract

Background and Objective

Domperidone is a drug used globally for relieving nausea and vomiting and stimulating breast milk production. Several case reports and studies linked domperidone usage with major cardiovascular adverse events (cardiac arrhythmia and sudden cardiac death). However, multiple randomized controlled efficacy studies failed to detect such adverse events. Our objectives were to systematically review and meta-analyze the association between current domperidone exposure and cardiovascular adverse events.

Methods

The first author performed EMBASE, PubMed and Scopus searches to identify human studies assessing the association between current domperidone exposure and cardiac arrhythmia or sudden death. Thirteen related articles were identified and the first and second authors independently reviewed the articles. Six studies were included in the final analysis. Meta-analysis was performed with a random effect model using the inverse variance approach. Heterogeneity was evaluated using the Q statistic and I 2 test.

Results

Five case-control studies and one case-crossover study were included in this meta-analysis. Pooled risk estimates demonstrated that the current use of domperidone increased the risk of ventricular arrhythmia and sudden cardiac death (pooled adjusted odds ratio = 1.70; 95 % confidence interval 1.47–1.97; I 2 = 0 %). The I 2 test showed that the underlying population was homogeneous.

Conclusions

Evidence from this meta-analysis suggests that current domperidone use increases the risk of cardiac arrhythmia and sudden cardiac death by 70 %. Domperidone usage in older populations should be discouraged. Larger observational studies or randomized controlled trials are needed to confirm the findings of this analysis.

Keywords

Cardiac Arrest Ventricular Arrhythmia Sudden Cardiac Death Metoclopramide Cisapride 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

Nattawut Leelakanok would like to acknowledge the support from The Royal Thai Government Scholarship. We thank Saket Girotra for his assistance. We also thank Xiaomei Gu for her help in developing search terms; Daniel Fife from Johnson & Johnson for his references list; Elizabeth Asztalos, Mathieu Pasquier, and Patrick Pun for providing useful information from their publications.

Compliance with Ethical Standards

Funding

There was no external source of funding. MLS receives salary support from a VA Health Services and Research Career Development Award (CDA 11-215).

Conflict of interest

NL, AH and MLS have no conflicts of interest to declare.

Supplementary material

40261_2015_360_MOESM1_ESM.docx (14 kb)
Supplementary material 1 (DOCX 14 kb)

References

  1. 1.
    Barone JA. Domperidone: a peripherally acting dopamine2-receptor antagonist. Ann Pharmacother. 1999;33(4):429–40.CrossRefPubMedGoogle Scholar
  2. 2.
    Patterson D, Abell T, Rothstein R, Koch K, Barnett J. A double-blind multicenter comparison of domperidone and metoclopramide in the treatment of diabetic patients with symptoms of gastroparesis. Am J Gastroenterol. 1999;94(5):1230–4.PubMedGoogle Scholar
  3. 3.
    Dumitrascu DL, Weinbeck M. Domperidone versus metoclopramide in the treatment of diabetic gastroparesis. Am J Gastroenterol. 2000;95(1):316–7.CrossRefPubMedGoogle Scholar
  4. 4.
    Franzese A, Borrelli O, Corrado G, Rea P, Di Nardo G, Grandinetti AL, et al. Domperidone is more effective than cisapride in children with diabetic gastroparesis. Aliment Pharmacol Ther. 2002;16(5):951–7.CrossRefPubMedGoogle Scholar
  5. 5.
    Sugumar A, Singh A, Pasricha PJ. A systematic review of the efficacy of domperidone for the treatment of diabetic gastroparesis. Clin Gastroenterol Hepatol. 2008;6(7):726–33.CrossRefPubMedGoogle Scholar
  6. 6.
    Vandenplas Y, Salvatore S, Hauser B. The diagnosis and management of gastro-oesophageal reflux in infants. Early Hum Dev. 2005;81(12):1011–24.CrossRefPubMedGoogle Scholar
  7. 7.
    Veldhuyzen van Zanten SJO, Jones MJ, Verlinden M, Talley NJ. Efficacy of cisapride and domperidone in functional (nonulcer) dyspepsia: a meta-analysis. Am J Gastroenterol. 2001;96(3):689–96.CrossRefPubMedGoogle Scholar
  8. 8.
    Doggrell SA, Hancox JC. Cardiac safety concerns for domperidone, an antiemetic and prokinetic, and galactogogue medicine. Expert Opin Drug Saf. 2014;13(1):131–8.CrossRefPubMedGoogle Scholar
  9. 9.
    Alvarez A, Ortiz AM, McCallum R, Sarosiek I. Cardiovascular safety profile of domperidone in a limited access program in the usa motility center. Gastroenterology. 2012;142(5):S845–6.CrossRefGoogle Scholar
  10. 10.
    Di Lorenzo CY, Nader N. Diagnosis and management of intestinal motility disorders. Semin Pediatr Surg. 2010;19(1):50–8.CrossRefPubMedGoogle Scholar
  11. 11.
    Osadchy A, Moretti ME, Koren G. Effect of domperidone on insufficient lactation in puerperal women: a systematic review and meta-analysis of randomized controlled trials. Obstet Gynecol Int. 2012;2012:642893.PubMedCentralPubMedGoogle Scholar
  12. 12.
    da Silva OP, Knoppert DC, Angelini MM, Forret PA. Effect of domperidone on milk production in mothers of premature newborns: a randomized, double-blind, placebo-controlled trial. CMAJ. 2001;164(1):17–21.PubMedCentralPubMedGoogle Scholar
  13. 13.
    Ingram J, Taylor H, Churchill C, Pike A, Greenwood R. Metoclopramide or domperidone for increasing maternal breast milk output: a randomised controlled trial. Arch Dis Child Fetal Neonatal Ed. 2012;97(4):F241–5.CrossRefPubMedGoogle Scholar
  14. 14.
    Jantarasaengaram S, Sreewapa P. Effects of domperidone on augmentation of lactation following cesarean delivery at full term. Int J Gynaecol Obstet. 2012;116(3):240–3.CrossRefPubMedGoogle Scholar
  15. 15.
    Wan EW, Davey K, Page-Sharp M, Hartmann PE, Simmer K, Ilett KF. Dose-effect study of domperidone as a galactagogue in preterm mothers with insufficient milk supply, and its transfer into milk. Br J Clin Pharmacol. 2008;66(2):283–9.PubMedCentralCrossRefPubMedGoogle Scholar
  16. 16.
    Stork D, Timin EN, Berjukow S, Huber C, Hohaus A, Auer M, et al. State dependent dissociation of HERG channel inhibitors. Br J Pharmacol. 2007;151(8):1368–76.PubMedCentralCrossRefPubMedGoogle Scholar
  17. 17.
    Rocha CM, Barbosa MM. QT interval prolongation associated with the oral use of domperidone in an infant. Pediatr Cardiol. 2005;26(5):720–3.CrossRefPubMedGoogle Scholar
  18. 18.
    Boyce MJ, Baisley KJ, Warrington SJ. Pharmacokinetic interaction between domperidone and ketoconazole leads to QT prolongation in healthy volunteers: a randomized, placebo-controlled, double-blind, crossover study. Br J Clin Pharmacol. 2012;73(3):411–21.PubMedCentralCrossRefPubMedGoogle Scholar
  19. 19.
    Djeddi D, Kongolo G, Lefaix C, Mounard J, Leke A. Effect of domperidone on QT interval in neonates. J Pediatr. 2008;153(5):663–6.CrossRefPubMedGoogle Scholar
  20. 20.
    Rossi M, Giorgi G. Domperidone and long QT syndrome. Curr Drug Saf. 2010;5(3):257–62.CrossRefPubMedGoogle Scholar
  21. 21.
    Giaccone G, Bertetto O, Calciati A. Two sudden deaths during prophylactic antiemetic treatment with high doses of domperidone and methylprednisolone. Lancet. 1984;2(8415):1336–7.CrossRefPubMedGoogle Scholar
  22. 22.
    Joss RA, Goldhirsch A, Brunner KW, Galeazzi RL. Sudden death in cancer patient on high-dose domperidone. Lancet. 1982;1(8279):1019.CrossRefPubMedGoogle Scholar
  23. 23.
    Roussak JB, Carey P, Parry H. Cardiac arrest after treatment with intravenous domperidone. Br Med J (Clin Res Ed). 1984;289(6458):1579.CrossRefGoogle Scholar
  24. 24.
    Bozzo P, Koren G, Ito S. Health Canada advisory on domperidone should I avoid prescribing domperidone to women to increase milk production? Can Fam Physician. 2012;58(9):952–3.PubMedCentralPubMedGoogle Scholar
  25. 25.
    U.S. Department of Health and Human Services, U.S. Food and Drug Administration. FDA cautions breast-feeding moms. FDA Consum. 2004;38(5):6. Available at: http://permanent.access.gpo.gov/lps1609/www.fda.gov/fdac/departs/2004/504_upd.html#moms .
  26. 26.
    Ortiz A, Cooper CJ, Alvarez A, Gomez Y, Sarosiek I, McCallum RW. Cardiovascular safety profile and clinical experience with high-dose domperidone therapy for nausea and vomiting. Am J Med Sci. 2015;349(5):421–4.PubMedCentralCrossRefPubMedGoogle Scholar
  27. 27.
    Czinn SJ, Blanchard S. Gastroesophageal reflux disease in neonates and infants: when and how to treat. Paediatr Drugs. 2013;15(1):19–27.CrossRefPubMedGoogle Scholar
  28. 28.
    Wells G, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2014 [cited June, 2015 4]; Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
  29. 29.
    Woolf B. On estimating the relation between blood group and disease. Ann Hum Genet. 1955;19(4):251–3.CrossRefPubMedGoogle Scholar
  30. 30.
    Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58.CrossRefPubMedGoogle Scholar
  31. 31.
    Straus SM, Sturkenboom MC, Bleumink GS, Dieleman JP, Van Der Lei J, De Graeff PA, et al. Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac death. Eur Heart J. 2005;26(19):2007–12.CrossRefPubMedGoogle Scholar
  32. 32.
    De Bruin ML, Langendijk PN, Koopmans RP, Wilde AA, Leufkens HG, Hoes AW. In-hospital cardiac arrest is associated with use of non-antiarrhythmic QTc-prolonging drugs. Br J Clin Pharmacol. 2006;63(2):216–23.PubMedCentralCrossRefPubMedGoogle Scholar
  33. 33.
    Jolly K, Gammage MD, Cheng KK, Bradburn P, Banting MV, Langman MJS. Sudden death in patients receiving drugs tending to prolong the QT interval. Br J Clin Pharmacol. 2009;68(5):743–51.PubMedCentralCrossRefPubMedGoogle Scholar
  34. 34.
    van Noord C, Dieleman JP, Verhamme K, Sturkenboom MC. Ventricular arrhythmia and sudden unexpected death and domperidone. Pharmacoepidememiol Drug Saf. 2009;18(S1):S155.Google Scholar
  35. 35.
    van Noord C, Dieleman JP, van Herpen G, Verhamme K, Sturkenboom MC. Domperidone and ventricular arrhythmia or sudden cardiac death: a population-based case-control study in the Netherlands. Drug Saf. 2010;33(11):1003–14.CrossRefPubMedGoogle Scholar
  36. 36.
    Johannes CB, Varas-Lorenzo C, McQuay LJ, Midkiff KD, Fife D. Risk of serious ventricular arrhythmia and sudden cardiac death in a cohort of users of domperidone: a nested case-control study. Pharmacoepidemiol Drug Saf. 2010;19(9):881–8.CrossRefPubMedGoogle Scholar
  37. 37.
    Arana A, Johannes C, Varas C, Rothman KJ, McQuay LJ, Yang Q, et al. Risk of out-of-hospital sudden cardiac death with use of domperidone, proton pump inhibitors, and metoclopramide. Pharmacoepidemiol Drug Saf. 2014;23:189.Google Scholar
  38. 38.
    Arana A, Johannes CB, McQuay LJ, Varas-Lorenzo C, Fife D, Rothman KJ. Risk of out-of-hospital sudden cardiac death in users of domperidone, proton pump inhibitors, or metoclopramide: a population-based nested case-control study. Drug Saf. 2015;38(12):1187–99.PubMedCentralCrossRefPubMedGoogle Scholar
  39. 39.
    Chen HL, Hsiao FY. Domperidone, cytochrome P450 3A4 isoenzyme inhibitors and ventricular arrhythmia: a nationwide case-crossover study. Pharmacoepidemiol Drug Saf. 2015;24(8):841–8.CrossRefPubMedGoogle Scholar
  40. 40.
    Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. In: Higgins JPT GS, editor. The Cochrane Collaboration, 2011; 2011.Google Scholar
  41. 41.
    Marzi M, Weitz D, Avila A, Molina G, Caraballo L, Piskulic L. Cardiac adverse effects of domperidone in adult patients: a systematic review. Rev Med Chil. 2015;143(1):14–21.CrossRefPubMedGoogle Scholar
  42. 42.
    Paul C, Zenut M, Dorut A, Coudore MA, Vein J, Cardot JM, et al. Use of domperidone as a galactagogue drug: a systematic review of the benefit-risk ratio. J Hum Lact. 2015;31(1):57–63.CrossRefPubMedGoogle Scholar
  43. 43.
    Manisty C, Hughes-Roberts Y, Kaddoura S. Cardiac manifestations and sequelae of gastrointestinal disorders. Br J Cardiol. 2009;16(4):6.Google Scholar
  44. 44.
    Scott JW. Gastrointestinal symptoms in cardiovascular disease. Can Med Assoc J. 1945;52(2):128–30.PubMedCentralPubMedGoogle Scholar
  45. 45.
    Chugh SS, Reinier K, Singh T, Uy-Evanado A, Socoteanu C, Peters D, et al. Determinants of prolonged QT interval and their contribution to sudden death risk in coronary artery disease: the Oregon Sudden Unexpected Death Study. Circulation. 2009;119(5):663–70.PubMedCentralCrossRefPubMedGoogle Scholar
  46. 46.
    Pun PH, Horton JR, Middleton JP. Dialysate calcium concentration and the risk of sudden cardiac arrest in hemodialysis patients. Clin J Am Soc Nephrol. 2013;8(5):797–803.PubMedCentralCrossRefPubMedGoogle Scholar
  47. 47.
    Asztalos EV, Campbell-Yeo M, daSilva OP, Kiss A, Knoppert DC, Ito S. Enhancing breast milk production with domperidone in mothers of preterm neonates (EMPOWER trial). BMC Pregnancy Childbirth. 2012;12:87.PubMedCentralCrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  1. 1.Department of Pharmaceutical Sciences and Experimental TherapeuticsCollege of Pharmacy, University of IowaIowa CityUSA
  2. 2.Department of EpidemiologyCollege of Public Health, University of IowaIowa CityUSA
  3. 3.Division of General Internal MedicineCarver College of Medicine, University of IowaIowa CityUSA
  4. 4.Iowa City VA Health Care SystemIowa CityUSA

Personalised recommendations